Platelets from two afibrinogenemic patients were used to
and both the prothrombin times and partial thromboplastin times were greater than 600 seconds (controls 13 seconds and 28 seconds respectively).
Neither patient had detectable amounts of plasma fibrinogen, as measured by the fibrin polymerization time (Bonomelli, Milan, Italy). gen that completely inhibited the potentiation of aggregation caused by the addition of fibrinogen (3 to 1 1 g/mL) ( Fig 5) .
RESULTS

Fibrinogen
(Control experiments were done with nonimmune F(ab')2 fragments.) However, an antibody to glycoprotein lIb/Illa (10E5) at a final concentration of 10 jzg/mL completely inhibited platelet aggregation induced by 10 to 20 tmol/L ADP but had no effect on the shape change of the platelets. There was little difference in the extent of aggregation and the release of granule contents of normal and afibrinogenemic platelets in response to thrombin (0.2 to I .0 U/mL; Fig  6) . In these experiments the addition of hirudin two minutes after thrombin did not lead to deaggregation of the platelets from either the normal or afibrinogenemic patient (data not shown). Aggregation by thrombin at a concentration of 0.2 U/mL or higher was not inhibited by the F(ab')2 fragments ofan antibody to human fibrinogen (Fig 6) .
Deaggregation.
To investigate the possible role of fibrinogen in preventing deaggregation, we examined the effect of 
